No Spin. Just The Source.
unga.news

The Nobel Winner Behind AlphaFold Just Raised $5 Billion to Design Drugs With SI

Demis Hassabis’s Isomorphic Labs closed the biggest venture round biotech has seen, six months after raising $2.1 billion. Now it has to get a drug into human trials.

By @UngaTheGreat ·
Share on XText
Image: Isomorphic Labs CEO Demis Hassabis at the 2024 Nobel Lectures in Stockholm. Photo: Jay Dixit via Wikimedia Commons, CC BY-SA 4.0

Six months ago, Isomorphic Labs raised $2.1 billion and it looked like a lot of money. On Tuesday, the London drug-design company said it had raised $5 billion more.

The Series C was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor and Alphabet putting in money again. Every existing backer came back too: Thrive Capital, MGX, GV, CapitalG, Temasek and the U.K. Sovereign AI Fund. The company called the round oversubscribed.

BioSpace called it the largest venture round in biotech history, according to R&D World, topping the $3 billion Altos Labs raised when it launched in 2022. Isomorphic didn’t disclose a valuation. Bloomberg reported Nov. 4 that the company was in talks to raise about $5 billion at roughly $50 billion.

Bar chart of Isomorphic Labs funding rounds: $600 million in March 2025, $2.1 billion in May 2026, and $5 billion in November 2026
Three rounds in 20 months. Sources: Isomorphic Labs announcements, March 31, 2025; May 12, 2026; Nov. 17, 2026.

The company Demis Hassabis left DeepMind to run

Isomorphic was spun out of Google DeepMind in 2021. Its founder is Sir Demis Hassabis, who shared the 2024 Nobel Prize in chemistry with John Jumper for AlphaFold, the DeepMind system that predicts the 3D shape of a protein from its genetic sequence. Knowing a protein’s shape is a big part of knowing how a drug might latch onto it.

This is the company’s first raise since Hassabis gave up running DeepMind. He stepped down as its chief executive in August, became DeepMind’s chairman and Alphabet’s chief scientist, and kept the CEO job at Isomorphic. Alphabet still controls the company. R&D World, citing U.K. Companies House filings, reported that Alphabet holds 75% or more of Isomorphic’s shares and voting rights.

“When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI,” Hassabis said in the company’s release. “Our drug design engine is generating molecules with unprecedented precision and speed.”

What $5 billion buys

The engine he means is called IsoDDE. Isomorphic describes it as a suite of simulation models that work across disease areas and different kinds of drugs, exploring huge numbers of possible molecules before a chemist ever makes one. The company pairs those models with what it calls proprietary agents that reason over complex biology.

The money goes four places, according to the release: making IsoDDE better, pushing into new kinds of biology and medicine, building what Isomorphic calls global infrastructure for SI-led bioengineering, and building the clinical machinery needed to move drug candidates into human trials.

That last part is the one that matters most. Isomorphic says its work is producing “positive preclinical results” in its own cancer and immune-system programs and in work with partners. It has deals with Eli Lilly, Novartis and Johnson & Johnson. But no Isomorphic drug has entered a clinical trial yet.

“This round enables us to accelerate our progress,” Hassabis said, including “driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients.”

Max Jaderberg, the company’s president, said the models are producing results on a weekly rhythm. “Every week we are making repeatable scientific advancements enabled by our models,” he said. “Our interdisciplinary teams combine world-leading machine learning researchers with top-class drug hunters.”

Why investors keep writing bigger checks

Drug development is slow and expensive. Most candidates fail somewhere between the lab and the pharmacy shelf, often after years of work. The pitch behind Isomorphic is that simulation can kill bad ideas early and find good ones faster, before anyone spends money making and testing molecules by hand.

Neil Mehta, founder of Greenoaks, called drug discovery “an optimization challenge of almost infinite scale.” Konstantine Buhler of Sequoia said the firm was proud to help “translate advanced AI into a growing portfolio of drug candidates.”

The investors are betting on more than one company. Isomorphic’s raises have climbed from $600 million in March 2025 to $2.1 billion in May to $5 billion now. BioSpace counts at least $7.7 billion raised since March 2025. Rivals are well funded too; Xaira Therapeutics launched in April 2024 with more than $1 billion committed.

Isomorphic also guards its tools more closely than DeepMind once did. AlphaFold 3, built with DeepMind, eventually had its code released and its weights opened for noncommercial use. IsoDDE got a technical report in February with no code, weights or training details. Isomorphic doesn’t sell access to its models. It uses them on its own drugs and its partners’.

The test that money can’t skip

For all the cash, Isomorphic still faces the same wall every drug company hits. A molecule designed by a computer has to prove itself in people, through the same trials and the same regulators as one found the old way.

The company says it now has the money to get there. The next proof won’t be another funding round. It will be the first Isomorphic drug dosed in a patient.

ShareShare on XText

Sources

  1. Isomorphic Labs (PR Newswire) — Isomorphic Labs announces $5 Billion Series C funding
  2. Isomorphic Labs on 𝕏 — We’ve closed our $5 Billion funding round
  3. TechCrunch — Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials
  4. R&D World — Isomorphic Labs raises $5 billion in biotech’s biggest venture round
  5. Isomorphic Labs — Isomorphic Labs announces Series B investment round
← Back to unga.news